Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells

Blood Cancer Journal

Volumn 6, Issue 7, 2016, Pages

  Starheim, K K ^a   Holien, T ^a   Misund, K ^a   Johansson, I ^a,b   Baranowska, K A ^a   Sponaas, A M ^a   Hella, H ^a   Buene, G ^a   Waage, A ^a,c   Sundan, A ^a   Bjorkoy G ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYSTEINE; GLUTATHIONE; PROTEASOME; TRANSCRIPTION FACTOR NRF2;

APOPTOSIS; CELL SURVIVAL; CLUSTER ANALYSIS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; HUMAN; INTRACELLULAR SPACE; METABOLISM; MULTIPLE MYELOMA; PHYSIOLOGICAL STRESS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORTEZOMIB; CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GLUTATHIONE; HUMANS; INTRACELLULAR SPACE; MULTIPLE MYELOMA; NF-E2-RELATED FACTOR 2; PROTEASOME ENDOPEPTIDASE COMPLEX; STRESS, PHYSIOLOGICAL;

EID: 85010514097     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/BCJ.2016.56     Document Type: Article

References (32)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324–339.
3. Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJL, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat 2015; 18: 18–35.
4. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508–513.
5. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076.
6. Anargyrou K, Dimopoulos M-A, Sezer O, Terpos E. Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma 2008; 49: 677–689.
7. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783–1792.
8. Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol 2008; 141: 494–503.
9. Xiong Y, Uys JD, Tew KD, Townsend DM. S-glutathionylation: from molecular mechanisms to health outcomes. Antioxid Redox Signal 2011; 15: 233–270.
10. Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 2015; 27: 1–12.
11. Lu SC. Glutathione synthesis. Biochim Biophys Acta 2013; 1830: 3143–3153.
12. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387–400.
13. Chen R-S, Song Y-M, Zhou Z-Y, Tong T, Li Y, Fu M et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 2009; 28: 599–609.
14. Lo M, Wang Y-Z, Gout PW. The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 2008; 215: 593–602.
15. Kinoshita H, Okabe H, Beppu T, Chikamoto A, Hayashi H, Imai K et al. Cystine/ glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma. Oncol Rep 2013; 29: 685–689.
16. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011; 16: 123–140.
17. Hoadley Ka, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014; 158: 929–944.
18. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106–109.
19. Sasaki H, Sato H, Kuriyama-Matsumura K, Sato K, Maebara K, Wang H et al. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J Biol Chem 2002; 277: 44765–44771.
20. Bjørkøy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171: 603–614.
21. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun J-A, Outzen H et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282: 24131–24145.
22. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010; 12: 213–223.
23. Ichimura Y, Waguri S, Sou Y-S, Kageyama S, Hasegawa J, Ishimura R et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 2013; 51: 618–631.
24. Lau A, Wang X-J, Zhao F, Villeneuve NF, Wu T, Jiang T et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 2010; 30: 3275–3285.
25. Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J 2001; 2: 42–53.
26. Hjertner O. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 2001; 97: 516–522.
27. Våtsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O et al. OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus. Leuk Res 2009; 33: 1670–1677.
28. Misund K, Baranowska KA, Holien T, Rampa C, Klein DCG, Borset M et al. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells. J Biomol Screen 2013; 18: 637–646.
29. Suraweera A, Münch C, Hanssum A, Bertolotti A. Failure of amino acid homeostasis causes cell death following proteasome inhibition. Mol Cell 2012; 6: 242–253.
30. Nagel D, Vincendeau M, Eitelhuber AC, Krappmann D. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies. Oncogene 2014; 33: 5655–5665.
31. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 2014 Apr; 39: 199–218.
32. Plosker GL, Croom KF. A review of its use in the management of rheumatoid arthritis. Drugs 2005; 65: 1825–1849.